Abstract
Introduction: COVID-19 vaccine efficacy has been evaluated in large clinical trials and in real-world situation. Although they have proven to be very effective in the general population, little is known about their efficacy in immunocompromised patients. HIV-infected individuals’ response to vaccine may vary according to the type of vaccine and their level of immunosuppression. We evaluated immunogenicity of an mRNA anti-SARS CoV-2 vaccine in HIV-positive individuals.
Methods: HIV-positive individuals (n = 121) were recruited from HIV clinics in Montreal and stratified according to their CD4 counts. A control group of 20 health care workers naïve to SARS CoV-2 was used. The participants’ Anti-RBD IgG responses were measured by ELISA at baseline and 3-4 weeks after receiving the first dose of an mRNA vaccine).
Results: Eleven of 121 participants had anti-COVID-19 antibodies at baseline, and a further 4 had incomplete data for the analysis. Mean anti-RBD IgG responses were similar between the HIV negative control group (n = 20) and the combined HIV+ group (n = 106) (p = 0.72). However, these responses were significantly lower in the group with <250 CD4 cells/mm 3 . (p < 0.0001). Increasing age was independently associated with decreased immunogenicity.
Conclusion: HIV-positive individuals with CD4 counts over 250 cells/mm 3 have an anti-RBD IgG response similar to the general population. However, HIV-positive individuals with the lowest CD4 counts (<250 cells/mm 3 ) have a weaker response. These data would support the hypothesis that a booster dose might be needed in this subgroup of HIV-positive individuals, depending on their response to the second dose.
Keywords: Covid-19 Vaccine immunogenicity; Covid-19 Vaccines in Immunocompromised Patients; Covid-19 Vaccines in people living with HIV; Vaccine immunogenicity HIV; mRNA Vaccines in people living with HIV; mRNA vaccine immunogenicity in people living with HIV.
【저자키워드】 Covid-19 Vaccine immunogenicity, Covid-19 Vaccines in Immunocompromised Patients, Covid-19 Vaccines in people living with HIV, Vaccine immunogenicity HIV, mRNA Vaccines in people living with HIV, mRNA vaccine immunogenicity in people living with HIV., 【초록키워드】 SARS CoV-2, HIV, Efficacy, Vaccine, COVID-19 vaccine, clinical trial, antibody, mRNA vaccine, Immunocompromised patients, Immunosuppression, CD4, ELISA, mRNA, response, Health care worker, age, General population, booster dose, Hypothesis, Analysis, Anti-RBD IgG, IgG response, Support, control group, second dose, first dose, individual, naïve, participant, CD4 counts, Montreal, HIV-positive individuals, significantly lower, HIV clinics, effective, negative control, lowest, was used, recruited, evaluated, receiving, were measured, Increasing, stratified, with HIV, baseline, CD4 count, HIV-positive individual, 【제목키워드】 HIV-1, vaccine immunogenicity,